The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitisTopline data expected in…
Award-winning health tech company brings prescription savings to over 38,700 pharmacies nationwideESTERO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Visory…
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused…
ROCKVILLE, Md., July 01, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.), a leader in reducing healthcare costs by providing high-quality…
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of…
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance…
Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic…
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…
Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO…